Activation of the TXNIP/NLRP3 inflammasome pathway contributes to inflammation in diabetic retinopathy: a novel inhibitory effect of minocycline

Inflammation Research

Volumn 66, Issue 2, 2017, Pages 157-166

  Chen, Wei ^a,b   Zhao, Minjie ^a   Zhao, Shuzhi ^a   Lu, Qianyi ^a   Ni, Lisha ^c   Zou, Chen ^a   Lu, Li ^d   Xu, Xun ^a   Guan, Huaijin ^b   Zheng, Zhi ^a   Qiu, Qinghua ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b NANTONG UNIVERSITY   (China)

^c LISHUI PEOPLE S HOSPITAL   (China)

^d ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

Diabetic retinopathy; Minocycline; NLRP3 inflammasome

Indexed keywords

CASPASE 3; CRYOPYRIN; GLUCOSE; INFLAMMASOME; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 6; LENTIVIRUS VECTOR; MESSENGER RNA; MINOCYCLINE; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA; THIOREDOXIN INTERACTING PROTEIN; TUMOR NECROSIS FACTOR; VASCULOTROPIN; ANTIINFLAMMATORY AGENT; CARRIER PROTEIN; NLRP3 PROTEIN, RAT; SMALL INTERFERING RNA; TXNIP PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BLOOD RETINA BARRIER; BLOOD VESSEL PERMEABILITY; BODY WEIGHT; CAPILLARY ENDOTHELIAL CELL; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETIC RETINOPATHY; ENZYME ACTIVITY; GENE SILENCING; GLUCOSE BLOOD LEVEL; HEK293 CELL LINE; HUMAN; HUMAN CELL; HYPERGLYCEMIA; INFLAMMATION; MALE; NONHUMAN; PATHOGENESIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RAT; RETINA; RETINA BLOOD VESSEL; RETINA CELL; RETINA TISSUE; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; CAPILLARY PERMEABILITY; CELL CULTURE; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; ENDOTHELIUM CELL; GENETICS; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; CAPILLARY PERMEABILITY; CARRIER PROTEINS; CASPASE 1; CASPASE 3; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; ENDOTHELIAL CELLS; GLUCOSE; HUMANS; INFLAMMASOMES; INFLAMMATION; INTERLEUKIN-18; INTERLEUKIN-1BETA; MALE; MINOCYCLINE; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING;

EID: 84992327335     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-016-1002-6     Document Type: Article

References (28)

1. Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2012;12:346–54.
2. El-Asrar AM. Role of inflammation in the pathogenesis of diabetic retinopathy. Middle East Afr J Ophthalmol. 2012;19:70–4.
3. Kowluru RA, Odenbach S. Role of interleukin-1beta in the pathogenesis of diabetic retinopathy. Br J Ophthalmol. 2004;88:1343–7.
4. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10:417–26.
5. Cassel SL, Joly S, Sutterwala FS. The NLRP3 inflammasome: a sensor of immune danger signals. Semin Immunol. 2009;21:194–8.
6. Leavy O. Inflammasome: turning on and off NLRP3. Nat Rev Immunol. 2013;13:1.
7. Michaudel C, Couturier-Maillard A, Chenuet P, et al. Inflammasome, IL-1 and inflammation in ozone-induced lung injury. Am J Clin Exp Immunol. 2016;5:33–40.
8. Perrone L, Devi TS, Hosoya K, Terasaki T, Singh LP. Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions. J Cell Physiol. 2009;221:262–72.
9. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol. 2010;11:136–40.
10. Perrone L, Devi TS, Hosoya KI, Terasaki T, Singh LP. Inhibition of TXNIP expression in vivo blocks early pathologies of diabetic retinopathy. Cell Death Dis. 2010;1:e65.
11. Li C, Yuan K, Schluesener H. Impact of minocycline on neurodegenerative diseases in rodents: a meta-analysis. Rev Neurosci. 2013;24:553–62.
12. Krady JK, Basu A, Allen CM, Xu Y, LaNoue KF, Gardner TW, et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes. 2005;54:1559–65.
13. Zheng Z, Chen H, Li J, Li T, Zheng B, Zheng Y, et al. Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin. Diabetes. 2012;61:217–28.
14. Leal EC, Martins J, Voabil P, Liberal J, Chiavaroli C, Bauer J, et al. Calcium dobesilate inhibits the alterations in tight junction proteins and leukocyte adhesion to retinal endothelial cells induced by diabetes. Diabetes. 2010;59:2637–45.
15. Kingsbury SR, Conaghan PG, McDermott MF. The role of the NLRP3 inflammasome in gout. J Inflamm Res. 2011;4:39–49.
16. Lee HM, Kim JJ, Kim HJ, Shong M, Ku BJ, Jo EK. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes. 2013;62:194–204.
17. Al-Shabrawey M, Zhang W, McDonald D. Diabetic retinopathy: mechanism, diagnosis, prevention, and treatment. BioMed Res Int. 2015;2015:854593.
18. Sagulenko V, Thygesen SJ, Sester DP, et al. AIM2 and NLRP3 inflammasomes activate both apoptotic and pyroptotic death pathways via ASC. Cell Death Differ. 2013;20:1149–60.
19. Shimada K, Crother TR, Karlin J, et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity. 2012;36:401–14.
20. Heid ME, Keyel PA, Kamga C, Shiva S, Watkins SC, Salter RD. Mitochondrial reactive oxygen species induces NLRP3-dependent lysosomal damage and inflammasome activation. J Immunol. 2013;191:5230–8.
21. Tschopp J, Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol. 2010;10:210–5.
22. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol. 2009;11:136–40.
23. Devi TS, Hosoya K-I, Terasaki T, Singh LP. Critical role of TXNIP in oxidative stress. DNA damage and retinal pericyte apoptosis under high glucose: Implications for diabetic retinopathy. Experimental cell research; 2013.
24. Szeto GL, Pomerantz JL, Graham DR, Clements JE. Minocycline suppresses activation of nuclear factor of activated T cells 1 (NFAT1) in human CD4+ T cells. J Biol Chem. 2011;286:11275–82.
25. Giuliani F, Hader W, Yong VW. Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell–microglia interaction. J Leukoc Biol. 2005;78:135–43.
26. Kraus RL, Pasieczny R, Lariosa-Willingham K, Turner MS, Jiang A, Trauger JW. Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J Neurochem. 2005;94:819–27.
27. Plane JM, Shen Y, Pleasure DE, Deng W. Prospects for minocycline neuroprotection. Arch Neurol. 2010;67:1442–8.
28. Bhatt LK, Addepalli V. Attenuation of diabetic retinopathy by enhanced inhibition of MMP-2 and MMP-9 using aspirin and minocycline in streptozotocin-diabetic rats. Am J Transl Res. 2010;2:181–9.